Belite Bio Inc

NASDAQ:BLTEUnited States

Nov 12, 2024

Show headlines and story abstract

• Belite Bio Q3 Net Loss Narrows, from 4:03AM ET on Tuesday Nov 12, 2024 by MT Newswires

  4:03AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: BLTE
  04:03 AM EST, 11/12/2024 (MT Newswires) -- Belite Bio (BLTE) reported a Q3 net loss Tuesday of $0.28 per diluted share, narrowing from a loss of $0.40 a year earlier. Analysts surveyed by Capital IQ expected a loss of $0.29. The company did not repo...

• Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update, from 1:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  1:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: BLTE
  
  This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words "expect", "hope", and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the "Risk Factors" section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.